Literature DB >> 6723689

Class 1 antiarrhythmic drugs--characteristic electrocardiographic differences when assessed by atrial and ventricular pacing.

J R Milne, K J Hellestrand, R S Bexton, P J Burnett, N M Debbas, A J Camm.   

Abstract

Class 1 antiarrhythmic drugs have been subdivided into 1a, 1b and 1c according to their effect on the action potential duration. The effects on the surface electrocardiogram of one drug from each subgroup were investigated in nine patients. Electrocardiographic recordings were taken during sinus rhythm and at identical atrial and ventricular paced rates. Disopyramide (1a) significantly prolonged the QT interval during sinus rhythm and at the identical paced rates, by increasing both the QRS duration and JT interval. Lignocaine (1b) significantly reduced the QT interval during sinus rhythm and at the identical paced rates, by reducing the JT interval. Lignocaine had no effect on the QRS duration. Flecainide (1c) significantly prolonged the QRS duration during sinus rhythm, but not the QTc. However the QT interval at the paced rates prolonged significantly, due entirely to an increase of the QRS duration. Flecainide had no effect on the JT interval. These characteristic electrocardiographic differences support the differentiation of class 1 drugs into three separate subgroups.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723689     DOI: 10.1093/oxfordjournals.eurheartj.a061633

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

1.  Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels.

Authors:  Stephan A Pless; Jason D Galpin; Adam Frankel; Christopher A Ahern
Journal:  Nat Commun       Date:  2011-06-14       Impact factor: 14.919

2.  Cardiac arrhythmias: theory and practice.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-06

3.  "Normal" response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: methodological aspects.

Authors:  K Nowinski; L Bergfeldt
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

4.  Diurnal variation of the QT interval--influence of the autonomic nervous system.

Authors:  R S Bexton; H O Vallin; A J Camm
Journal:  Br Heart J       Date:  1986-03

5.  Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.

Authors:  A J Camm; K J Hellestrand; A W Nathan; R S Bexton
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans.

Authors:  L Bergfeldt; K Schenck-Gustafsson; R Dahlqvist
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 7.  The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology.

Authors:  Christiaan C Veerman; Arthur A M Wilde; Elisabeth M Lodder
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

Review 8.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 9.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

10.  Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?

Authors:  Jorge Romero; Samuel H Baldinger; David Goodman-Meza; Krysthel Engstrom; Carolina R Valencia; Anjani Golive; Francisco Medrano; Sabarivinoth Rangasamy; Mohammed Makkiya; John D Fisher; Jay Gross; Andrew Krumerman; Soo Kim; Mario J Garcia; Luigi Di Biase; Kevin J Ferrick
Journal:  J Interv Card Electrophysiol       Date:  2015-11-20       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.